Improved survival of multiple myeloma patients with late relapse after high-dose treatment and stem cell support, a population-based study of 348 patients in Denmark in 1994-2004

Annette Juul Vangsted, Tobias Klausen, Niels Frost Andersen, Niels Abildgaard , Anne O. Gang, Henrik Gregersen, Ulla Vogel, Peter Gimsing

    Research output: Contribution to journalJournal articleResearchpeer-review

    Abstract

    Objective: To analyse if patients with early relapse after high-dose hemotherapy with stem cell support (HDT) benefit from new treatment strategies in a population-based setting. Methods: We conducted a retrospective study of relapse treatment and survival in 348 patients undergoing HDT in Denmark in
    1994–2004. Patients were divided into two groups according to time-to-treatment failure (i) within 18 months after HDT and (ii) later than 18 months after HDT. The fraction of patients surviving 3 yr after first relapse was evaluated in relation to calendar periods for introduction of new drugs: before the introduction of thalidomide (1995–1999), before the introduction of bortezomib and lenalidomide (2000–2002) and when patients had access to all treatment modalities (2003–2008). Results: Two hundred and forty-three patients suffered from relapse which required treatment. The median follow-up time was
    91.4 months (60–158.8 months) and overall survival was 56.3 months after HDT. The fraction of patients alive 3 yr after first relapse increased in the periods after the year 2000 for patients with late relapse: 1995–1999, 36%; 2000–2002, 57%; and 2003–2008, 72% (P = 0.03), in contrast to patients with early relapse: 1995–1999, 25%; 2000–2002, 33%; and 2003–2008, 31% (P = 0.7). Conclusion: Improved survival was only observed among patients with late relapse after HDT and this may be because of increased use of salvage HDT, improved supportive care and introduction of new drugs.
    Original languageEnglish
    JournalEuropean Journal of Haematology
    Volume85
    Issue number3
    Pages (from-to)209-216
    ISSN0902-4441
    DOIs
    Publication statusPublished - 2010

    Keywords

    • multiple myeloma
    • new treatment strategies
    • survival

    Cite this

    Vangsted, Annette Juul ; Klausen, Tobias ; Andersen, Niels Frost ; Abildgaard , Niels ; Gang, Anne O. ; Gregersen, Henrik ; Vogel, Ulla ; Gimsing, Peter. / Improved survival of multiple myeloma patients with late relapse after high-dose treatment and stem cell support, a population-based study of 348 patients in Denmark in 1994-2004. In: European Journal of Haematology. 2010 ; Vol. 85, No. 3. pp. 209-216.
    @article{a5bd1f9def144ee29e5b6fbbe293465d,
    title = "Improved survival of multiple myeloma patients with late relapse after high-dose treatment and stem cell support, a population-based study of 348 patients in Denmark in 1994-2004",
    abstract = "Objective: To analyse if patients with early relapse after high-dose hemotherapy with stem cell support (HDT) benefit from new treatment strategies in a population-based setting. Methods: We conducted a retrospective study of relapse treatment and survival in 348 patients undergoing HDT in Denmark in 1994–2004. Patients were divided into two groups according to time-to-treatment failure (i) within 18 months after HDT and (ii) later than 18 months after HDT. The fraction of patients surviving 3 yr after first relapse was evaluated in relation to calendar periods for introduction of new drugs: before the introduction of thalidomide (1995–1999), before the introduction of bortezomib and lenalidomide (2000–2002) and when patients had access to all treatment modalities (2003–2008). Results: Two hundred and forty-three patients suffered from relapse which required treatment. The median follow-up time was 91.4 months (60–158.8 months) and overall survival was 56.3 months after HDT. The fraction of patients alive 3 yr after first relapse increased in the periods after the year 2000 for patients with late relapse: 1995–1999, 36{\%}; 2000–2002, 57{\%}; and 2003–2008, 72{\%} (P = 0.03), in contrast to patients with early relapse: 1995–1999, 25{\%}; 2000–2002, 33{\%}; and 2003–2008, 31{\%} (P = 0.7). Conclusion: Improved survival was only observed among patients with late relapse after HDT and this may be because of increased use of salvage HDT, improved supportive care and introduction of new drugs.",
    keywords = "multiple myeloma, new treatment strategies, survival",
    author = "Vangsted, {Annette Juul} and Tobias Klausen and Andersen, {Niels Frost} and Niels Abildgaard and Gang, {Anne O.} and Henrik Gregersen and Ulla Vogel and Peter Gimsing",
    year = "2010",
    doi = "10.1111/j.1600-0609.2010.01465.x",
    language = "English",
    volume = "85",
    pages = "209--216",
    journal = "European Journal of Haematology",
    issn = "0902-4441",
    publisher = "Wiley-Blackwell Publishing, Inc",
    number = "3",

    }

    Improved survival of multiple myeloma patients with late relapse after high-dose treatment and stem cell support, a population-based study of 348 patients in Denmark in 1994-2004. / Vangsted, Annette Juul; Klausen, Tobias; Andersen, Niels Frost; Abildgaard , Niels; Gang, Anne O.; Gregersen, Henrik; Vogel, Ulla; Gimsing, Peter.

    In: European Journal of Haematology, Vol. 85, No. 3, 2010, p. 209-216.

    Research output: Contribution to journalJournal articleResearchpeer-review

    TY - JOUR

    T1 - Improved survival of multiple myeloma patients with late relapse after high-dose treatment and stem cell support, a population-based study of 348 patients in Denmark in 1994-2004

    AU - Vangsted, Annette Juul

    AU - Klausen, Tobias

    AU - Andersen, Niels Frost

    AU - Abildgaard , Niels

    AU - Gang, Anne O.

    AU - Gregersen, Henrik

    AU - Vogel, Ulla

    AU - Gimsing, Peter

    PY - 2010

    Y1 - 2010

    N2 - Objective: To analyse if patients with early relapse after high-dose hemotherapy with stem cell support (HDT) benefit from new treatment strategies in a population-based setting. Methods: We conducted a retrospective study of relapse treatment and survival in 348 patients undergoing HDT in Denmark in 1994–2004. Patients were divided into two groups according to time-to-treatment failure (i) within 18 months after HDT and (ii) later than 18 months after HDT. The fraction of patients surviving 3 yr after first relapse was evaluated in relation to calendar periods for introduction of new drugs: before the introduction of thalidomide (1995–1999), before the introduction of bortezomib and lenalidomide (2000–2002) and when patients had access to all treatment modalities (2003–2008). Results: Two hundred and forty-three patients suffered from relapse which required treatment. The median follow-up time was 91.4 months (60–158.8 months) and overall survival was 56.3 months after HDT. The fraction of patients alive 3 yr after first relapse increased in the periods after the year 2000 for patients with late relapse: 1995–1999, 36%; 2000–2002, 57%; and 2003–2008, 72% (P = 0.03), in contrast to patients with early relapse: 1995–1999, 25%; 2000–2002, 33%; and 2003–2008, 31% (P = 0.7). Conclusion: Improved survival was only observed among patients with late relapse after HDT and this may be because of increased use of salvage HDT, improved supportive care and introduction of new drugs.

    AB - Objective: To analyse if patients with early relapse after high-dose hemotherapy with stem cell support (HDT) benefit from new treatment strategies in a population-based setting. Methods: We conducted a retrospective study of relapse treatment and survival in 348 patients undergoing HDT in Denmark in 1994–2004. Patients were divided into two groups according to time-to-treatment failure (i) within 18 months after HDT and (ii) later than 18 months after HDT. The fraction of patients surviving 3 yr after first relapse was evaluated in relation to calendar periods for introduction of new drugs: before the introduction of thalidomide (1995–1999), before the introduction of bortezomib and lenalidomide (2000–2002) and when patients had access to all treatment modalities (2003–2008). Results: Two hundred and forty-three patients suffered from relapse which required treatment. The median follow-up time was 91.4 months (60–158.8 months) and overall survival was 56.3 months after HDT. The fraction of patients alive 3 yr after first relapse increased in the periods after the year 2000 for patients with late relapse: 1995–1999, 36%; 2000–2002, 57%; and 2003–2008, 72% (P = 0.03), in contrast to patients with early relapse: 1995–1999, 25%; 2000–2002, 33%; and 2003–2008, 31% (P = 0.7). Conclusion: Improved survival was only observed among patients with late relapse after HDT and this may be because of increased use of salvage HDT, improved supportive care and introduction of new drugs.

    KW - multiple myeloma

    KW - new treatment strategies

    KW - survival

    U2 - 10.1111/j.1600-0609.2010.01465.x

    DO - 10.1111/j.1600-0609.2010.01465.x

    M3 - Journal article

    VL - 85

    SP - 209

    EP - 216

    JO - European Journal of Haematology

    JF - European Journal of Haematology

    SN - 0902-4441

    IS - 3

    ER -